{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:51:13Z","timestamp":1787597473354,"version":"build-2736575974"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2304800"],"award-info":[{"award-number":["2022YFC2304800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Risk factors that influence the outcome of patients with chronic hepatitis C (CHC) are not fully understood. The systemic immune-inflammatory index (SII) is an independent prognostic factor for multiple diseases. However, the impact of the SII on the outcome of liver fibrosis is unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This prospective real-world study enrolled patients with CHC treated with sofosbuvir\/velpatasvir. Logistic regression models were used to investigate the relationship between the SII and the outcome of liver fibrosis in treatment-naive patients. Liver fibrosis was assessed using aspartate aminotransferase-to-platelet ratio index (APRI) and fibrosis-4 index (FIB-4).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 288 participants, the SII was 238.2 (153.0\u2013358.2). The non-improved outcomes of liver fibrosis assessed with APRI (non-improved APRI) and FIB-4 (non-improved FIB-4) were 83.0 and 87.5%, respectively. Adjusted models showed that the SII was positively associated with non-improved APRI (adjusted OR (95% CI): 1.013 (1.009\u20131.017), <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001) and FIB-4 (adjusted OR (95% CI): 1.004 (1.001\u20131.007), <jats:italic>p<\/jats:italic>\u202f=\u202f0.012). Similarly, a higher SII was associated with a higher risk of non-improved APRI (adjusted OR (95% CI): 13.53 (5.60\u201332.68), <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001) and FIB-4 (adjusted OR (95% CI): 5.69 (2.17\u201314.90), <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001). The association with non-improved APRI was much more remarkable in patients with alanine aminotransferase &amp;lt;2 ULN, and the association with non-improved FIB-4 was remarkable in patients aged &amp;lt;50\u202fyears. Multiple imputation analyses confirmed the robustness of these results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings suggested that the SII was positively associated with non-improved outcomes of liver fibrosis in patients with CHC. These results need to be validated in large-scale prospective cohorts.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1486503","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T04:23:45Z","timestamp":1732595025000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Association between the systemic immune-inflammation index and the outcome of liver fibrosis in patients with chronic hepatitis C"],"prefix":"10.3389","volume":"11","author":[{"given":"Yuanji","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyao","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3390\/ijms20061358","article-title":"Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular carcinoma in chronic hepatitis B and C infections: a review","volume":"20","author":"Kanda","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"Electronic address: ee, chair: CPGP, representative: EGB, panel members:. EASL recommendations on treatment of hepatitis C: final update of the series(\u2606)","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.hbpd.2020.02.004","article-title":"Long-term follow-up of HCV patients with sustained virological response after treatment with pegylated interferon plus ribavirin","volume":"20","author":"Ma","year":"2021","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jhep.2016.10.017","article-title":"Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication","volume":"66","author":"van der Meer","year":"2017","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/liv.13596","article-title":"Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens","volume":"38","author":"Reddy","year":"2018","journal-title":"Liver Int"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-14-0442","article-title":"Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma","volume":"20","author":"Hu","year":"2014","journal-title":"Clin Cancer Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"7131","DOI":"10.2147\/JIR.S345790","article-title":"Systemic immune-inflammatory index as a predictor of lymph node metastasis in endometrial Cancer","volume":"14","author":"Lei","year":"2021","journal-title":"J Inflamm Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"20585","DOI":"10.18632\/aging.203449","article-title":"Prognostic and clinicopathological significance of systemic immune-inflammation index in pancreatic cancer: a meta-analysis of 2,365 patients","volume":"13","author":"Shui","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"633480","DOI":"10.3389\/pore.2021.633480","article-title":"Prognostic value of the C-reactive protein\/albumin ratio and systemic immune-inflammation index for patients with colorectal liver metastasis undergoing curative resection","volume":"27","author":"Deng","year":"2021","journal-title":"Pathol Oncol Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.2147\/JIR.S421491","article-title":"Association of Systemic Inflammatory Response Index and Pan-Immune-Inflammation-Value with Long-term adverse cardiovascular events in ST-segment elevation myocardial infarction patients after primary percutaneous coronary intervention","volume":"16","author":"Liu","year":"2023","journal-title":"J Inflamm Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.2147\/JIR.S432506","article-title":"The systemic immune inflammatory response index can predict the clinical prognosis of patients with initially diagnosed coronary artery disease","volume":"16","author":"Li","year":"2023","journal-title":"J Inflamm Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12974-023-02890-y","article-title":"The relationship between systemic inflammation index, systemic immune-inflammatory index, and inflammatory prognostic index and 90-day outcomes in acute ischemic stroke patients treated with intravenous thrombolysis","volume":"20","author":"Ma","year":"2023","journal-title":"J Neuroinflammation"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1087345","DOI":"10.3389\/fimmu.2023.1087345","article-title":"Association of systemic immune inflammatory index with all-cause and cause-specific mortality in hypertensive individuals: results from NHANES","volume":"14","author":"Cao","year":"2023","journal-title":"Front Immunol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1097\/HJH.0000000000003560","article-title":"Threshold effect of systemic immune inflammatory index on hypertension in American adults (NHANES 2017-2020)","volume":"41","author":"Shi","year":"2023","journal-title":"J Hypertens"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.numecd.2023.09.025","article-title":"Association between systemic immune inflammatory\/inflammatory response index and hypertension: a cohort study of functional community","volume":"34","author":"Ma","year":"2024","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1186\/s12872-023-03638-5","article-title":"Association of systemic immune inflammatory index with all-cause and cause-specific mortality among individuals with type 2 diabetes","volume":"23","author":"Chen","year":"2023","journal-title":"BMC Cardiovasc Disord"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1331159","DOI":"10.3389\/fpubh.2023.1331159","article-title":"Association between systemic immune-inflammatory index and diabetes mellitus: mediation analysis involving obesity indicators in the NHANES","volume":"11","author":"Chen","year":"2023","journal-title":"Front Public Health"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1334811","DOI":"10.3389\/fendo.2024.1334811","article-title":"Nonlinear association of the systemic immune-inflammatory index with mortality in diabetic patients","volume":"15","author":"Meng","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1116224","DOI":"10.3389\/fimmu.2023.1116224","article-title":"Association between the systemic immune-inflammation index and kidney stone: a cross-sectional study of NHANES 2007-2018","volume":"14","author":"Di","year":"2023","journal-title":"Front Immunol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1337241","DOI":"10.3389\/fimmu.2024.1337241","article-title":"Systemic immune-inflammatory biomarkers (SII, NLR, PLR and LMR) linked to non-alcoholic fatty liver disease risk","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"925690","DOI":"10.3389\/fimmu.2022.925690","article-title":"Association between SII and hepatic steatosis and liver fibrosis: a population-based study","volume":"13","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"21535","DOI":"10.1038\/s41598-024-72447-3","article-title":"Association between systemic immune inflammation index and short term prognosis of acute on chronic liver failure","volume":"14","author":"Ma","year":"2024","journal-title":"Sci Rep"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12916-018-1162-z","article-title":"Pathways to ensure universal and affordable access to hepatitis C treatment","volume":"16","author":"Douglass","year":"2018","journal-title":"BMC Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.3760\/cma.j.cn501113-20221220-00605","article-title":"Guideline for the prevention and treatment of hepatitis C (2022 version)","volume":"30","year":"2022","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(23)01320-X","article-title":"Hepatitis C","volume":"402","author":"Martinello","year":"2023","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jhep.2020.10.016","article-title":"HCC surveillance after SVR in patients with F3\/F4 fibrosis","volume":"74","author":"Ioannou","year":"2021","journal-title":"J Hepatol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/labinvest.3780165","article-title":"Clonal analysis of micronodules in virus C-induced liver cirrhosis using laser capture microdissection (LCM) and HUMARA assay","volume":"80","author":"Paradis","year":"2000","journal-title":"Lab Investig"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.dld.2018.09.016","article-title":"Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals","volume":"51","author":"Casadei Gardini","year":"2019","journal-title":"Dig Liver Dis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.7150\/jca.25691","article-title":"Prognostic value of systemic immune-inflammation index in cancer: a meta-analysis","volume":"9","author":"Yang","year":"2018","journal-title":"J Cancer"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/j.devcel.2021.05.011","article-title":"Tissue mechanics in stem cell fate, development, and cancer","volume":"56","author":"Hayward","year":"2021","journal-title":"Dev Cell"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41586-022-05289-6","article-title":"Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis","volume":"610","author":"Filliol","year":"2022","journal-title":"Nature"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s15010-018-1136-2","article-title":"Serum YKL-40 as a biomarker for liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT","volume":"46","author":"Yan","year":"2018","journal-title":"Infection"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/apt.12921","article-title":"Systematic review: identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring--predictors and predictive models of disease progression","volume":"40","author":"Konerman","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.3390\/jcm8101676","article-title":"Predictive effects of inflammatory scores in patients with BCLC 0-a hepatocellular carcinoma after hepatectomy","volume":"8","author":"Huang","year":"2019","journal-title":"J Clin Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1002\/hep.25832","article-title":"Resection of hepatocellular cancer \u22642 cm: results from two Western centers","volume":"57","author":"Roayaie","year":"2013","journal-title":"Hepatology"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.14218\/JCTH.2016.00056","article-title":"Immune dysfunction in cirrhosis","volume":"5","author":"Noor","year":"2017","journal-title":"J Clin Transl Hepatol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ejphar.2017.03.063","article-title":"Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment: a preliminary study","volume":"806","author":"Stasi","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/jvh.13058","article-title":"Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir","volume":"26","author":"Kong","year":"2019","journal-title":"J Viral Hepat"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/jvh.12814","article-title":"Interpretation of liver stiffness measurement-based approach for the monitoring of hepatitis B patients with antiviral therapy: a 2-year prospective study","volume":"25","author":"Liang","year":"2018","journal-title":"J Viral Hepat"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14218\/JCTH.2019.00040","article-title":"Liver stiffness measurement can reflect the active liver Necroinflammation in population with chronic liver disease: a real-world evidence study","volume":"7","author":"Wang","year":"2019","journal-title":"J Clin Transl Hepatol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.14309\/ajg.0000000000001239","article-title":"Unreliable estimation of fibrosis regression during treatment by liver stiffness measurement in patients with chronic hepatitis B","volume":"116","author":"Ji","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3851\/IMP1726","article-title":"On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients","volume":"16","author":"Wong","year":"2011","journal-title":"Antivir Ther"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3390\/v14020333","article-title":"Factors associated with significant platelet count improvement in thrombocytopenic chronic hepatitis C patients receiving direct-acting antivirals","volume":"14","author":"Chen","year":"2022","journal-title":"Viruses"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/hepr.13426","article-title":"Rapid increase of platelet counts during antiviral therapy in patients with hepatitis C virus infection","volume":"50","author":"Ishizu","year":"2020","journal-title":"Hepatol Res"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12876-021-01606-x","article-title":"Baseline thrombopoietin level is associated with platelet count improvement in thrombocytopenic chronic hepatitis C patients after successful direct-acting antiviral agent therapy","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Gastroenterol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1486503\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T04:23:49Z","timestamp":1732595029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1486503\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":49,"alternative-id":["10.3389\/fmed.2024.1486503"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1486503","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"article-number":"1486503"}}